BioStem Technologies (OTCMKTS:BSEM) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

BioStem Technologies (OTCMKTS:BSEM) posted its quarterly earnings results on Tuesday. The company reported 0.32 EPS for the quarter, beating analysts’ consensus estimates of 0.31 by 0.01, Zacks reports. The business had revenue of 82.56 million for the quarter, compared to the consensus estimate of 78.22 million.

BioStem Technologies Stock Down 6.5 %

BioStem Technologies stock traded down 1.63 during midday trading on Thursday, reaching 23.36. 115,357 shares of the stock traded hands, compared to its average volume of 32,583. The stock has a market cap of $388.16 million, a P/E ratio of 34.35 and a beta of -0.36. The stock’s fifty day moving average is 13.28 and its 200-day moving average is 10.64. BioStem Technologies has a 12 month low of 2.34 and a 12 month high of 28.26.

BioStem Technologies Company Profile

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.